Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 16;16(2):e0246195.
doi: 10.1371/journal.pone.0246195. eCollection 2021.

Dehydroepiandrostenedione sulphate (DHEAS) levels predict high risk of rheumatoid arthritis (RA) in subclinical hypothyroidism

Affiliations

Dehydroepiandrostenedione sulphate (DHEAS) levels predict high risk of rheumatoid arthritis (RA) in subclinical hypothyroidism

Ravindra Shukla et al. PLoS One. .

Abstract

Introduction: The presence of rheumatism is well recognized in primary hypothyroidism. Dehydroepiandrstenedione sulphate (DHEAS) is associated with rheumatological diseases like rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). This study aims to explore relationship between joint pains and DHEAS levels in primary hypothyroidism.

Methods: Retrospective study of 78 subjects with subclinical hypothyroidism, with TSH within reference range. The joint pains were evaluated by European Union League against rheumatism (EULAR-CSA) score and compared with serum DHEAS, RA factor, Anti-TPO antibody, highly sensitive C-recative protein (hsCRP), vitamin D levels.

Result: DHEAS levels <43.6 mcg/dl significantly predicted clinical features of pre RA as assessed by EULAR CSA criteria with acceptable specificity (82%). EULAR CSA score is fairly valid in assessing imminent RA in primary hypothyroidism.

Conclusion: Lower DHEAS predicts clinical features of imminent RA in subjects with primary hypothyroidism. This is akin to low DHEAS seen in many rheumatological disease with possibly similar mechanism. Another possibility is low DHEAS alters hepato-hypothalamo pituitary adrenal axis in presense of cytokines and induces a hitherto unrecognized state of pre rheumatoid arthritis like syndrome. Future studies on primary hypothyroidism should focus on role of lower DHEAS levels in inducing symptoms of fatigue and joint pains.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Study flow chart.
Of total 462 datasets screened, 78 datasets were included in present study.
Fig 2
Fig 2. Inverse correlation between age and DHEAS levels.
The correlation was weak (spearman rho coefficient of correlation = -0.241) but statistically significant (0.03).
Fig 3
Fig 3. Low DHEAS as predictor of rheumatism in primary hypothyroidism.
ROC curve for low DHEAS as a predictor of rheumatism in primary hypothyroidism. The AUC curve was 0.67 (C.I = 0.52–0.83, p = 0.021).The cut off point for <43.6 mcg/dl was found. DHEAS, 43.8 predicted CSA of >5 with 82% specificity but low sensitivity (52%).
Fig 4
Fig 4. Comparison of mean DHEAS according to CSA status.
CSA was considered present if CSA score was greater or equal to 4. The mean DHEAS of those with CSA present (125.29 +/- 26.81) was lower than those with CSA absent (80.60 = /- 10). However it was not statistically significant. (p = 0.17).

Similar articles

Cited by

References

    1. Emamifar A, Hangaard J, Jensen Hansen IM. Thyroid disorders in patients with newly diagnosed rheumatoid arthritis is associated with poor initial treatment response evaluated by disease activity score in 28 joints-C-reactive protein (DAS28-CRP): An observational cohort study. Medicine (Baltimore). 2017;96(43): e8357 10.1097/MD.0000000000008357 - DOI - PMC - PubMed
    1. van Steenbergen HW, Aletaha D, Beaart-van de Voorde LJJ, Brouwer E, Codreanu C, Combe B, et al. EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. Ann Rheum Dis 2016. –209846 10.1136/annrheumdis-2016-209846 - DOI - PubMed
    1. Rutkowski K, Sowa P, Rutkowska-Talipska J, Kuryliszyn-Moskal A, Rutkowski R. Dehydroepiandrosterone (DHEA): hypes and hopes. Drugs. 2014;74(11):1195–1207. 10.1007/s40265-014-0259-8 - DOI - PubMed
    1. Tagawa N, Tamanaka J, Fujinami A, Kobayashi Y, Takano T, Fukata S, et al. Serum dehydroepiandrosterone, dehydroepiandrosterone sulfate, and pregnenolone sulfate concentrations in patients with hyperthyroidism and hypothyroidism. Clin Chem 2000. April;46(4):523–8. - PubMed
    1. Kadam P, Bhalerao S. Sample size calculation. Int J Ayurveda Res 2010;1(1):55–7. 10.4103/0974-7788.59946 - DOI - PMC - PubMed

Substances